Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination

Lefeuvre, M.; Kerneuzet, I.; Darrieux, Laure; Safa, Gilles

doi:10.1016/j.annder.2022.02.001

Cited by 5 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We concluded, based on the local epidemiologic context and the differentiating serology results, that a postinfectious association was unlikely. Our 2 pediatric cases add to an expanding case series of MIS-V. 8,[19][20][21][22][23][24][25][26][27][28][29][30][31][32] Other reported MIS-V cases are questionable in light of prior SARS-CoV-2 infections. [8][9][10][11][12][13][14][15][16][17][18] Both of our cases reported could simply be caused by KD unrelated to SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children

et al. 2022

View full text Add to dashboard Cite

This report presents 2 pediatric cases of multisystem inflammatory syndrome in children/adults (MIS-C/A) post-SARS-CoV-2 Vaccination (MIS-V). Both children presented with MIS-V within 6 weeks of receiving their first and only dose of Pfizer/BioNTech’s SARS-CoV-2 vaccine. The first patient had symptoms of MIS-C/A with peri-myocarditis and shock, and the second one had classic Kawasaki Disease (KD) features. Both responded well to intravenous immunoglobulins and/or systemic corticosteroids. Both children were positive only for SARS-2-CoV anti-spike (S) (and not for anti-nucleocapsid (NC)) antibodies consistent with a post-vaccine and not a post-infection event. Surveillance for rare adverse events (AE) following immunization should continue especially now that SARS-CoV-2 vaccination is approved in the 5-11 year age group that has had the highest risk of developing MIS-C post SARS-CoV-2 infection. Our patients did not receive any further SARS-CoV-2 vaccines. Our report highlights the importance of measuring differentiating antibodies (anti-S and anti-NC) that can be used within a specific timeframe to help determine if a patient has MIS-V post vaccine (only anti-S present), or MIS-C/A post SARS-CoV-2 infection (both anti-S and anti-NC present).

show abstract

Section: Discussionmentioning

confidence: 73%

“…[8][9][10][11][12][13][14][15][16][17][18] Initial cases of MIS-V (without previous SARS-CoV-2 infection) have been reported. 8,[19][20][21][22][23][24][25][26][27][28][29][30][31][32] We describe 2 MIS-V cases in Canadian children. Parental consent was obtained to publish these findings.…”

mentioning

confidence: 95%

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Table 1 [ 8 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ] and Table 2 [ 39 40 41 42 43 44 ] presents the results obtained from evaluation of 31 eligible articles retrieved from the databases.…”

Section: Resultsmentioning

confidence: 99%

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Yousefian

Khadivi

2023

Clin Exp Vaccine Res

View full text Add to dashboard Cite

The fast development of vaccines against the novel coronavirus disease is among the most critical steps taken to control this potentially fatal viral disease. Like other vaccines, the coronavirus disease 2019 (COVID-19) vaccines can also cause unwanted reactions. Erythema multiforme (EM) is among the oral mucocutaneous side effects of COVID-19 vaccines. This study aimed to comprehensively review the reported cases of EM since the global onset of COVID-19 vaccination. Data from 31 relevant studies regarding the type and dose of COVID-19 vaccines administered, time of initiation of symptoms, age, and gender of patients, site of involvement, patients’ medical history, and treatment options were extracted. In total, 90 patients were identified with EM as a side effect of COVID-19 vaccination across studies. EM had the highest frequency after receiving the first dose of mRNA vaccines in older individuals. The first symptoms of EM appeared in less than 3 days in 45% and after 3 days in 55% of patients. EM is not a common side effect of COVID-19 vaccination, and fear of its occurrence should not impede vaccination.

show abstract

“…Multisystem inflammatory syndrome has also been described following SARS-CoV-2 vaccination (MIS-V). The main difference in relation to MIS-C and MIS-A lies in the shorter time between initial exposure and onset of MIS symptoms [11] , [12] , [13] . This supports the hypothesis of a hyperinflammatory state leading to immune dysregulation and cytokine storm, even if the exact physiopathology remains unknown.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous exanthema revealing Multisystem-Inflammatory Syndrome in adults (MIS-A) in the course of SARS-CoV-2 infection

Pernea

Annabi

Walter

et al. 2023

Annales de Dermatologie et de Vénéréologie

View full text Add to dashboard Cite

Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination

Cited by 5 publications

References 21 publications

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Cutaneous exanthema revealing Multisystem-Inflammatory Syndrome in adults (MIS-A) in the course of SARS-CoV-2 infection

Contact Info

Product

Resources

About